Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.82 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.82 |
| ▸ | ABL1 | P00519 | 2/20 | 0.82 |
| ▸ | FNTA | P49354 | 1/20 | 0.73 |
| ▸ | FNTB | P49356 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | PDE5A | O76074 | 1/20 | 0.59 |
| ▸ | PDE1A | P54750 | 1/20 | 0.59 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.59 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.59 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177162 | 0.90 | RET (1.00) | RETALKABL1FNTAFNTB | |
| SCHEMBL1177261 | 0.80 | RET (0.77) | RETALKABL1FNTAFNTB | |
| SCHEMBL14584392 | 0.78 | PDE5A (0.78) | ALDH1A1RXFP1KDM4EMAPTPDE5A | |
| SCHEMBL16294281 | 0.77 | KDM4E (0.75) | RETALKABL1ALDH1A1MAPK1 | |
| SCHEMBL1177896 | 0.77 | FNTA (0.77) | RETALKABL1FNTAFNTB | |
| SCHEMBL16294693 | 0.77 | RXFP1 (0.91) | RETALKABL1FNTAFNTB | |
| SCHEMBL16294386 | 0.76 | RET (0.67) | RETALKABL1FNTAFNTB | |
| SCHEMBL1177621 | 0.76 | FNTA (0.80) | RETALKABL1FNTAFNTB | |
| SCHEMBL16294267 | 0.75 | RXFP1 (0.79) | RETALKABL1FNTAFNTB | |
| SCHEMBL16294387 | 0.75 | RXFP1 (0.73) | RETALKABL1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| EP-4234549-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | RET 4140/4885ALK 3824/4885ABL1 4567/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | RET 1741/4885ALK 4109/4885ABL1 2688/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | RET 1741/4885ALK 4109/4885ABL1 2688/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | RET 2096/4885ALK 4361/4885ABL1 3727/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | RET 2694/4885ALK 4324/4885ABL1 3729/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | RET 3161/4885ALK 4216/4885ABL1 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.